RAPP · Rapport Therapeutics Inc. Common Stock
View on chartInsiders & Stakes
| Third Rock Ventures V, L.P. | ▼ Sell | Open Market | 6,280,525 Shares held | 5/26/2026 | View profile |
| ARCH Venture Partners XII, LLC 10% Owner | ▼ Sell | Other | 3,728,738 Shares held | 6/10/2024 | View profile |
| Abraham Ceesay Chief Executive Officer | ▼ Sell | Open Market | 452,245 Shares held | 10/7/2026 | View profile |
| Bredt David Chief Scientific Officer | ▲ Buy | Option Exercise | 393,075 Shares held | 2/19/2026 | View profile |
| Yeleswaram Krishnaswamy Chief Development Officer | ▼ Sell | Open Market | 195,862 Shares held | 8/25/2026 | View profile |
| Gault Cheryl Chief Operating Officer | ▼ Sell | Open Market | 139,914 Shares held | 9/30/2026 | View profile |
| PAUL STEVEN M Director | ▲ Buy | Open Market | 41,666 Shares held | 9/12/2025 | View profile |
| James Healy Director | ▲ Buy | Open Market | 40,851 Shares held | 7/1/2024 | View profile |
| Huber Reid M Director | ▲ Buy | Open Market | 20,400 Shares held | 9/12/2025 | View profile |
| Ignelzi Troy A. Chief Financial Officer | ▲ Buy | Open Market | 10,000 Shares held | 3/13/2025 | View profile |
| Young Wendy B. | ▲ Buy | Open Market | 9,500 Shares held | 9/11/2025 | View profile |
Transaction History
| Abraham Ceesay | ▼ Sell | Open Market | 1,147 | $35K | 10/7/2026 |
| Abraham Ceesay | ▼ Sell | Open Market | 3,375 | $108K | 10/6/2026 |
| Gault Cheryl | ▼ Sell | Open Market | 7,925 | $262K | 9/30/2026 |
| Gault Cheryl | ▼ Sell | Open Market | 2,075 | $70K | 9/30/2026 |
| Abraham Ceesay | ▼ Sell | Open Market | 1,952 | $76K | 9/23/2026 |
| Abraham Ceesay | ▼ Sell | Open Market | 215 | $9K | 9/23/2026 |
| Abraham Ceesay | ▼ Sell | Open Market | 43 | $2K | 9/23/2026 |
| Abraham Ceesay | ▼ Sell | Open Market | 7,141 | $325K | 9/8/2026 |
| Abraham Ceesay | ▼ Sell | Open Market | 1,069 | $49K | 9/8/2026 |
| Abraham Ceesay | ▼ Sell | Open Market | 18,921 | $938K | 8/25/2026 |
| Yeleswaram Krishnaswamy | ▼ Sell | Open Market | 20,799 | $1.0M | 8/25/2026 |
| Yeleswaram Krishnaswamy | ▼ Sell | Open Market | 16,201 | $827K | 8/25/2026 |
| Yeleswaram Krishnaswamy | ▼ Sell | Open Market | 13,160 | $658K | 8/24/2026 |
| Yeleswaram Krishnaswamy | ▼ Sell | Open Market | 404 | $20K | 8/19/2026 |
| Abraham Ceesay | ▼ Sell | Open Market | 3,664 | $172K | 8/11/2026 |
| Abraham Ceesay | ▼ Sell | Open Market | 19,500 | $937K | 8/11/2026 |
| Abraham Ceesay | ▼ Sell | Open Market | 5,794 | $282K | 8/11/2026 |
| Abraham Ceesay | ▼ Sell | Open Market | 14,171 | $651K | 8/10/2026 |
| Abraham Ceesay | ▼ Sell | Open Market | 8,370 | $391K | 8/10/2026 |
| Abraham Ceesay | ▼ Sell | Open Market | 2,203 | $93K | 7/27/2026 |
| Abraham Ceesay | ▼ Sell | Open Market | 7 | $299 | 7/27/2026 |
| Abraham Ceesay | ▼ Sell | Open Market | 5,481 | $218K | 7/14/2026 |
| Abraham Ceesay | ▼ Sell | Open Market | 2,729 | $111K | 7/14/2026 |
| Gault Cheryl | ▼ Sell | Open Market | 1,900 | $76K | 6/30/2026 |
| Gault Cheryl | ▼ Sell | Open Market | 3,792 | $157K | 6/30/2026 |
| Gault Cheryl | ▼ Sell | Open Market | 3,308 | $140K | 6/30/2026 |
| Gault Cheryl | ▼ Sell | Open Market | 1,000 | $43K | 6/30/2026 |
| Abraham Ceesay | ▼ Sell | Open Market | 7,344 | $292K | 6/29/2026 |
| Abraham Ceesay | ▼ Sell | Open Market | 876 | $35K | 6/29/2026 |
| Third Rock Ventures V, L.P. | ▼ Sell | Open Market | 18,572 | $744K | 5/26/2026 |
| Third Rock Ventures V, L.P. | ▼ Sell | Open Market | 133,618 | $5.4M | 5/11/2026 |
| Third Rock Ventures V, L.P. | ▼ Sell | Open Market | 5,018 | $202K | 5/8/2026 |
| Third Rock Ventures V, L.P. | ▼ Sell | Open Market | 271,495 | $10.9M | 5/7/2026 |
| Yeleswaram Krishnaswamy | ▼ Sell | Open Market | 20,225 | $809K | 4/17/2026 |
| Third Rock Ventures V, L.P. | ▼ Sell | Open Market | 426,005 | $17.2M | 4/17/2026 |
| Yeleswaram Krishnaswamy | ▼ Sell | Open Market | 10,200 | $358K | 4/14/2026 |
| Yeleswaram Krishnaswamy | ▼ Sell | Open Market | 9,165 | $321K | 4/13/2026 |
| Yeleswaram Krishnaswamy | ▼ Sell | Open Market | 500 | $17K | 4/10/2026 |
| Yeleswaram Krishnaswamy | ▼ Sell | Open Market | 360 | $13K | 4/8/2026 |
| Gault Cheryl | ▼ Sell | Open Market | 7,161 | $201K | 3/30/2026 |
| Gault Cheryl | ▼ Sell | Open Market | 2,839 | $81K | 3/30/2026 |
| Yeleswaram Krishnaswamy | ▼ Sell | Open Market | 10,115 | $303K | 3/25/2026 |
| Gault Cheryl | ▼ Sell | Open Market | 2,014 | $58K | 3/5/2026 |
| Bredt David | ▲ Buy | Option Exercise | 6,000 | $11K | 2/19/2026 |
| Abraham Ceesay | ▼ Sell | Open Market | 3,552 | $103K | 2/18/2026 |
| Abraham Ceesay | ▼ Sell | Open Market | 2,281 | $68K | 2/18/2026 |
| Abraham Ceesay | ▼ Sell | Open Market | 2,983 | $87K | 2/18/2026 |
| Abraham Ceesay | ▼ Sell | Open Market | 2,100 | $63K | 2/18/2026 |
| Bredt David | ▼ Sell | Open Market | 900 | $25K | 2/17/2026 |
| Bredt David | ▼ Sell | Open Market | 5,400 | $156K | 2/17/2026 |
| Bredt David | ▼ Sell | Open Market | 2,200 | $65K | 2/17/2026 |
| Abraham Ceesay | ▼ Sell | Open Market | 5,833 | $152K | 1/20/2026 |
| Abraham Ceesay | ▼ Sell | Open Market | 5,083 | $133K | 1/20/2026 |
| Bredt David | ▼ Sell | Open Market | 8,300 | $223K | 1/15/2026 |
| Bredt David | ▼ Sell | Open Market | 200 | $5K | 1/15/2026 |
| Bredt David | ▲ Buy | Grant | 18,000 | — | 12/31/2025 |
| Bredt David | ▼ Sell | Open Market | 6,567 | $197K | 12/31/2025 |
| Yeleswaram Krishnaswamy | ▼ Sell | Open Market | 2,840 | $85K | 12/31/2025 |
| Yeleswaram Krishnaswamy | ▲ Buy | Grant | 9,000 | — | 12/31/2025 |
| Abraham Ceesay | ▼ Sell | Open Market | 2,147 | $62K | 12/17/2025 |
| Abraham Ceesay | ▼ Sell | Open Market | 2,421 | $73K | 12/17/2025 |
| Abraham Ceesay | ▼ Sell | Open Market | 515 | $16K | 12/17/2025 |
| Abraham Ceesay | ▼ Sell | Open Market | 2,441 | $70K | 12/17/2025 |
| Abraham Ceesay | ▼ Sell | Open Market | 2,792 | $84K | 12/17/2025 |
| Abraham Ceesay | ▼ Sell | Open Market | 600 | $19K | 12/17/2025 |
| Bredt David | ▼ Sell | Open Market | 7,704 | $231K | 12/15/2025 |
| Bredt David | ▼ Sell | Open Market | 796 | $24K | 12/15/2025 |
| Gault Cheryl | ▲ Buy | Option Exercise | 5,000 | $9K | 11/26/2025 |
| Gault Cheryl | ▼ Sell | Open Market | 5,000 | $150K | 11/26/2025 |
| Abraham Ceesay | ▼ Sell | Open Market | 2,777 | $69K | 11/17/2025 |
| Abraham Ceesay | ▼ Sell | Open Market | 3,056 | $78K | 11/17/2025 |
| Abraham Ceesay | ▼ Sell | Open Market | 2,242 | $56K | 11/17/2025 |
| Abraham Ceesay | ▼ Sell | Open Market | 2,841 | $72K | 11/17/2025 |
| Bredt David | ▼ Sell | Open Market | 3,156 | $78K | 11/17/2025 |
| Bredt David | ▼ Sell | Open Market | 5,344 | $136K | 11/17/2025 |
| Bredt David | ▼ Sell | Open Market | 7,418 | $191K | 10/15/2025 |
| Bredt David | ▼ Sell | Open Market | 1,082 | $28K | 10/15/2025 |
| Abraham Ceesay | ▼ Sell | Open Market | 4,647 | $120K | 10/15/2025 |
| Abraham Ceesay | ▼ Sell | Open Market | 1,186 | $31K | 10/15/2025 |
| Abraham Ceesay | ▼ Sell | Open Market | 4,328 | $111K | 10/15/2025 |
| Abraham Ceesay | ▼ Sell | Open Market | 755 | $20K | 10/15/2025 |
| Abraham Ceesay | ▼ Sell | Open Market | 39,435 | $1.0M | 9/17/2025 |
| Abraham Ceesay | ▼ Sell | Open Market | 1,400 | $38K | 9/17/2025 |
| Abraham Ceesay | ▼ Sell | Open Market | 34,885 | $918K | 9/17/2025 |
| Abraham Ceesay | ▼ Sell | Open Market | 700 | $19K | 9/17/2025 |
| Bredt David | ▼ Sell | Open Market | 5,098 | $122K | 9/15/2025 |
| Bredt David | ▼ Sell | Open Market | 3,402 | $84K | 9/15/2025 |
| Huber Reid M | ▲ Buy | Open Market | 20,400 | $499K | 9/12/2025 |
| PAUL STEVEN M | ▲ Buy | Open Market | 28,284 | $693K | 9/12/2025 |
| PAUL STEVEN M | ▲ Buy | Open Market | 13,382 | $334K | 9/12/2025 |
| Young Wendy B. | ▲ Buy | Open Market | 3,500 | $79K | 9/11/2025 |
| Gault Cheryl | ▲ Buy | Option Exercise | 5,000 | $9K | 9/8/2025 |
| Gault Cheryl | ▼ Sell | Open Market | 5,000 | $192K | 9/8/2025 |
| Bredt David | ▼ Sell | Open Market | 8,300 | $124K | 8/15/2025 |
| Bredt David | ▼ Sell | Open Market | 200 | $3K | 8/15/2025 |
| Bredt David | ▼ Sell | Open Market | 8,500 | $119K | 7/15/2025 |
| Bredt David | ▼ Sell | Open Market | 8,500 | $94K | 6/16/2025 |
| Bredt David | ▼ Sell | Open Market | 8,500 | $81K | 5/15/2025 |
| Bredt David | ▼ Sell | Open Market | 8,500 | $81K | 4/15/2025 |
| Bredt David | ▼ Sell | Open Market | 8,500 | $92K | 3/14/2025 |
| Ignelzi Troy A. | ▲ Buy | Open Market | 100 | $998 | 3/13/2025 |
| Ignelzi Troy A. | ▲ Buy | Open Market | 9,900 | $100K | 3/12/2025 |
| Young Wendy B. | ▲ Buy | Open Market | 6,000 | $61K | 3/12/2025 |
| Gault Cheryl | ▲ Buy | Grant | 13,987 | $0 | 3/3/2025 |
| James Healy | ▲ Buy | Open Market | 3,538 | $82K | 7/1/2024 |
| James Healy | ▲ Buy | Open Market | 3,565 | $86K | 7/1/2024 |
| James Healy | ▲ Buy | Open Market | 4,544 | $114K | 7/1/2024 |
| James Healy | ▲ Buy | Open Market | 2,559 | $67K | 7/1/2024 |
| James Healy | ▲ Buy | Open Market | 3,799 | $88K | 7/1/2024 |
| James Healy | ▲ Buy | Open Market | 4,878 | $122K | 7/1/2024 |
| James Healy | ▲ Buy | Open Market | 2,748 | $72K | 7/1/2024 |
| James Healy | ▲ Buy | Open Market | 3,630 | $84K | 7/1/2024 |
| James Healy | ▲ Buy | Open Market | 3,657 | $89K | 7/1/2024 |
| James Healy | ▲ Buy | Open Market | 4,661 | $117K | 7/1/2024 |
| James Healy | ▲ Buy | Open Market | 2,625 | $68K | 7/1/2024 |
| James Healy | ▲ Buy | Open Market | 3,828 | $93K | 7/1/2024 |
| ARCH Venture Partners XII, LLC | ▼ Sell | Other | 3,728,738 | $0 | 6/10/2024 |
| Third Rock Ventures V, L.P. | ▼ Sell | Other | 6,551,449 | $0 | 6/10/2024 |
| Third Rock Ventures V, L.P. | ▼ Sell | Other | 969,218 | $0 | 6/10/2024 |
| James Healy | ▼ Sell | Other | 1,392,738 | $0 | 6/10/2024 |
| James Healy | ▲ Buy | Open Market | 470,589 | $8.0M | 6/10/2024 |
| James Healy | ▲ Buy | Open Market | 18,641 | $317K | 6/10/2024 |
| James Healy | ▲ Buy | Open Market | 17,861 | $304K | 6/10/2024 |
| James Healy | ▲ Buy | Open Market | 26,278 | $447K | 6/10/2024 |
| James Healy | ▲ Buy | Open Market | 25,455 | $433K | 6/10/2024 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
Guggenheim initiates coverage of Rapport Therapeutics, sets $65 target
Guggenheim began coverage of Rapport Therapeutics and assigned a price target of $65. The target sits above the company's 52‑week high of $52.93, indicating a positive outlook. The stock currently trades with a low RSI and near a strong support level, which may influence market reaction to the new estimate.
Guggenheim initiates coverage of Rapport Therapeutics, sets $65 target. Guggenheim began coverage of Rapport Therapeutics and assigned a price target of $65. The target sits above the company's 52‑week high of $52.93, indicating a positive outlook. The stock currently trades with a low RSI and near a strong support level, which may influence market reaction to the new estimate.